Adorial augments novel drug discovery
C4X Discovery Holdings PLC (LON:C4XD)'s £1.67m purchase of Adorial provides access to a technology platform that should enable C4X to accelerate the identification of novel drug targets and associated development of small molecule drugs. The deal complements C4X’s rational drug design technology and fits its strategic ambition of becoming a highly efficient and productive drug discovery engine, targeting up to 15 new development projects over the next three years.
Adorial’s technology platform, Taxonomy3, has been used on a fee-for-service basis by large pharma companies such as Takeda and UCB Pharma. Using highly sensitive in silico (computer modelling) mining and analysis of publicly available DNA databases, Taxonomy3 holds the potential to identify previously unknown linkages and interactions between genes and biological pathways across a broad range of diseases. In turn, this could lead to the discovery of novel targets that cause disease and therefore form the basis for developing new drug candidates and/or biomarkers, which could help improve patient stratification and ultimately the chances of clinical success.
To read the entire report Please click on the pdf File Below